enGene Therapeutics Inc. (ENGN)

NASDAQ: ENGN · Real-Time Price · USD

1.850

-0.070 (-3.65%)

At close: Sep 9, 2026, 4:00 PM EDT

1.850

0.00 (0.00%)

After-hours: Sep 9, 2026, 4:43 PM EDT

enGene Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 31, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Cash & Equivalents	41.03	50.15	173	81.52	20.43	11.02
Short-Term Investments	225.3	143.58	65.33	-	-	-
Cash & Short-Term Investments	266.32	193.74	238.33	81.52	20.43	11.02
Cash Growth	31.90%	-18.71%	192.36%	298.95%	85.48%	-
Other Receivables	0.98	2.23	1.03	2.34	1.34	1.62
Receivables	0.98	2.23	1.03	2.34	1.34	1.62
Prepaid Expenses	10.53	5.35	7.93	1.5	0.74	0.8
Other Current Assets	0.08	0.08	0.07	0.08	0.07	0.08
Total Current Assets	277.9	201.39	247.36	85.44	22.58	13.52
Property, Plant & Equipment	9.03	10.19	2.91	0.59	0.39	0.57
Long-Term Investments	-	8.52	59.53	-	-	-
Other Long-Term Assets	1.39	1.36	1.37	0.93	0.94	0.94
Total Assets	288.32	221.47	311.17	86.96	23.91	15.03

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 31, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Accounts Payable	2.54	6.69	1.41	1.16	0.72	1
Accrued Expenses	22.22	14.68	11.9	3.39	3.09	1.09
Current Portion of Long-Term Debt	0.2	8	0.7	0.56	1.27	1.05
Current Portion of Leases	2.25	2.01	0.42	-	-	0.06
Current Income Taxes Payable	-	0.02	-	0.04	0.02	-
Other Current Liabilities	-	0.58	0.23	0.11	-	0.02
Total Current Liabilities	27.21	31.98	14.66	5.26	5.1	3.22
Long-Term Debt	25.16	15.32	22.47	9.22	27.05	2.45
Long-Term Leases	5.67	6.46	1.43	-	-	-
Other Long-Term Liabilities	-	-	-	-	3.79	0.6
Total Liabilities	58.03	53.76	38.56	14.47	35.95	6.26

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 31, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Common Stock	632.02	513.28	509.81	259.37	16.39	16.36
Additional Paid-In Capital	64.13	27.35	18.95	13.72	7.68	7.59
Retained Earnings	-464.51	-372.03	-254.73	-199.59	-99.67	-75.21
Comprehensive Income & Other	-1.35	-0.89	-1.42	-1.02	-1.02	-2.18
Total Common Equity	230.29	167.71	272.61	72.49	-76.61	-53.44
Shareholders' Equity	230.29	167.71	272.61	72.49	-12.04	8.76
Total Liabilities & Equity	288.32	221.47	311.17	86.96	23.91	15.03

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 31, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Total Debt	33.27	31.8	25.02	9.78	28.32	3.55
Net Cash (Debt)	233.05	161.94	213.31	71.74	-7.89	7.46
Net Cash Growth	36.66%	-24.08%	197.32%	-	-	-
Net Cash Per Share	3.61	3.17	5.65	103.58	-12.04	2.09
Filing Date Shares Outstanding	69.73	66.98	50.98	23.2	3.89	3.56
Total Common Shares Outstanding	69.73	52.02	50.98	23.2	3.69	3.56
Working Capital	250.69	169.41	232.7	80.18	17.48	10.3
Book Value Per Share	3.30	3.22	5.35	3.12	-20.77	-15.00
Tangible Book Value	230.29	167.71	272.61	72.49	-76.61	-53.44
Tangible Book Value Per Share	3.30	3.22	5.35	3.12	-20.77	-15.00
Machinery	-	4.17	2.39	2.12	1.75	1.8
Leasehold Improvements	-	0.26	0.24	0.13	0.12	0.13

SEC Filings: 10-K · 10-Q